Progestogen-only pills are considered safe at every age and every smoking category by contraceptive eligibility guidelines, which is why switching to one is the guideline default around age 50 rather than a fallback compromise.

The drospirenone-only pill is a newer option in this category, studied in women aged 18-45, and phase 3 data found it highly effective at preventing pregnancy with no clotting events reported and a wider missed-pill window than older progestogen-only pills. Its use specifically in women aged 46-55 is inferred from that younger age range rather than separately studied. All three drospirenone-only pill efficacy and tolerability studies cited in this file were conducted with authors employed by the pill's manufacturer, which is worth knowing when weighing the results.

What to know about this answer

There is no real clinical dispute that progestogen-only pills are a safe default at this age; the honest tension is a conflict-of-interest flag rather than a two-sided scientific debate, since the drospirenone-only pill's key efficacy and bleeding studies were authored by researchers employed by the manufacturer.

What the research shows, and which source each finding rests on

Progestogen-only pills are rated as no restriction at every age and every smoking category by contraceptive eligibility guidelines, and are not associated with increased risk of clotting, stroke, or heart attack, nor shown to affect bone density.

A[1]

In pooled phase 3 data covering 1,571 women aged 18-45 across over 14,000 exposure cycles, the drospirenone-only pill had a Pearl Index (pregnancy rate) of 0.73, with no cases of deep vein clot or pulmonary embolism reported.

B[2]

In a trial of women with proven ovulatory cycles who had four scheduled 24-hour delays in taking the drospirenone-only pill, ovulation still occurred in only 0.8% of cycles, giving it a wider missed-pill safety window than traditional progestogen-only pills.

B[3]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

the trial data support the drospirenone-only pill as a strong option

the published phase 3 and bleeding-profile studies

The pregnancy-prevention rate is very good, no clotting events occurred in the pooled trials, and bleeding profiles compared favorably with an older progestogen-only pill, including in subgroups such as women over 35, women with higher BMI, and smokers.

D[4]

the sponsor relationship should be disclosed whenever these numbers are cited

a standard scientific caution applied to industry-funded research

All three of the studies establishing the drospirenone-only pill's efficacy, missed-pill safety window, and bleeding profile compared with an older pill were conducted with authors employed by the manufacturer, which does not invalidate the findings but should be disclosed whenever they are surfaced.

B[2]B[3]D[4]

What would settle it: Independent, non-industry-funded replication of the efficacy and bleeding-profile findings, and dedicated study of the pill specifically in women aged 46-55, would close both gaps.

What is really going on here

  1. The drospirenone-only pill's efficacy data come from women aged 18-45; its use in women 46-55 is an extrapolation from that range, not a separately studied age group.
  2. There is no evidence that this pill, or any progestogen-only pill, provides adequate endometrial protection if systemic estrogen is added on top of it; guidelines state there is no evidence to support that use for older progestogen-only pills specifically.

Questions for your doctor

  1. Am I a good candidate for a progestogen-only pill given my health history?
  2. If I add estrogen later for symptoms, does this pill protect my uterine lining, or would I need something else for that?
  3. How forgiving is this pill if I occasionally miss a dose?
  4. What bleeding pattern should I expect when switching to this from my current method?

Questions with no answer yet

Does the drospirenone-only pill's strong trial performance hold up in independent, non-industry-funded research, given that every efficacy and bleeding-profile study so far was authored by researchers employed by the manufacturer?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: All three of the studies establishing the drospirenone-only pill's efficacy, missed-pill safety window, and bleeding profile compared with an older pill were conducted with authors employed by the manufacturer; this does not invalidate the findings but has not yet been independently replicated.

What would test it: Independent, non-industry-funded replication of the efficacy and bleeding-profile findings.

Does the drospirenone-only pill provide adequate endometrial protection if systemic estrogen is added on top of it, the way some clinicians are already combining it in practice?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: There is no evidence that this pill, or any progestogen-only pill, provides adequate endometrial protection if systemic estrogen is added on top of it; guidelines state there is no evidence to support that use for older progestogen-only pills specifically, and the drospirenone-only pill's efficacy data come from women aged 18-45, with its use in women 46-55 extrapolated from that range rather than separately studied.

What would test it: A trial testing endometrial safety specifically in women combining the drospirenone-only pill with added systemic estrogen, and a dedicated efficacy study in women aged 46-55.

Sources

  1. 1.U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. · Systematic review or guideline
  2. 2.Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill.Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand 2019;98(12):1549-57. · Randomised trial
  3. 3.Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake.Duijkers IJM, Heger-Mahn D, Drouin D, Colli E, Skouby S. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception 2016;93(4):303-9. · Randomised trial
  4. 4.Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg.Regidor PA, Palacios S, Colli E. Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg. Gynecol Endocrinol 2022;38(4):333-8. · Comparative or small study

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides